Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

Chad E. Mire; Joan B. Geisbert; Viktoriya Borisevich; Karla A. Fenton; Krystle N. Agans; Andrew I. Flyak; Daniel J. Deer; Herta Steinkellner; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Andrew Hiatt; Do H. Kim; Michael H. Pauly; Jesus Velasco; Kevin J. Whaley; James E. Crowe; Larry Zeitlin; Thomas W. Geisbert

doi:10.1126/scitranslmed.aai8711

Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

Chad E. Mire, Joan B. Geisbert, Viktoriya Borisevich, Karla A. Fenton, Krystle N. Agans, Andrew I. Flyak, Daniel J. Deer, Herta Steinkellner, Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do H. Kim, Michael H. Pauly, Jesus Velasco, Kevin J. Whaley, James E. Crowe, Larry Zeitlin, Thomas W. Geisbert

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

Original language	English (US)
Article number	eaai8711
Journal	Science Translational Medicine
Volume	9
Issue number	384
DOIs	https://doi.org/10.1126/scitranslmed.aai8711
State	Published - Apr 5 2017

ASJC Scopus subject areas

General Medicine

Access to Document

10.1126/scitranslmed.aai8711

Cite this

Mire, C. E., Geisbert, J. B., Borisevich, V., Fenton, K. A., Agans, K. N., Flyak, A. I., Deer, D. J., Steinkellner, H., Bohorov, O., Bohorova, N., Goodman, C., Hiatt, A., Kim, D. H., Pauly, M. H., Velasco, J., Whaley, K. J., Crowe, J. E., Zeitlin, L., & Geisbert, T. W. (2017). Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody. Science Translational Medicine, 9(384), Article eaai8711. https://doi.org/10.1126/scitranslmed.aai8711

Mire, CE, Geisbert, JB, Borisevich, V, Fenton, KA, Agans, KN, Flyak, AI, Deer, DJ, Steinkellner, H, Bohorov, O, Bohorova, N, Goodman, C, Hiatt, A, Kim, DH, Pauly, MH, Velasco, J, Whaley, KJ, Crowe, JE, Zeitlin, L & Geisbert, TW 2017, 'Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody', Science Translational Medicine, vol. 9, no. 384, eaai8711. https://doi.org/10.1126/scitranslmed.aai8711

@article{388d24dd43174b2ebd9c1511dee52414,

title = "Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody",

abstract = "As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.",

author = "Mire, {Chad E.} and Geisbert, {Joan B.} and Viktoriya Borisevich and Fenton, {Karla A.} and Agans, {Krystle N.} and Flyak, {Andrew I.} and Deer, {Daniel J.} and Herta Steinkellner and Ognian Bohorov and Natasha Bohorova and Charles Goodman and Andrew Hiatt and Kim, {Do H.} and Pauly, {Michael H.} and Jesus Velasco and Whaley, {Kevin J.} and Crowe, {James E.} and Larry Zeitlin and Geisbert, {Thomas W.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors.",

year = "2017",

month = apr,

day = "5",

doi = "10.1126/scitranslmed.aai8711",

language = "English (US)",

volume = "9",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "384",

}

TY - JOUR

T1 - Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

AU - Mire, Chad E.

AU - Geisbert, Joan B.

AU - Borisevich, Viktoriya

AU - Fenton, Karla A.

AU - Agans, Krystle N.

AU - Flyak, Andrew I.

AU - Deer, Daniel J.

AU - Steinkellner, Herta

AU - Bohorov, Ognian

AU - Bohorova, Natasha

AU - Goodman, Charles

AU - Hiatt, Andrew

AU - Kim, Do H.

AU - Pauly, Michael H.

AU - Velasco, Jesus

AU - Whaley, Kevin J.

AU - Crowe, James E.

AU - Zeitlin, Larry

AU - Geisbert, Thomas W.

PY - 2017/4/5

Y1 - 2017/4/5

N2 - As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

AB - As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

UR - http://www.scopus.com/inward/record.url?scp=85017420711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017420711&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aai8711

DO - 10.1126/scitranslmed.aai8711

M3 - Article

C2 - 28381540

AN - SCOPUS:85017420711

SN - 1946-6234

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 384

M1 - eaai8711

ER -

Therapeutic treatment of marburg and ravn virus infection in nonhuman primates with a human monoclonal antibody

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this